The news of the price target increase for CME Group by Keefe, Bruyette & Woods is likely to have a neutral impact on the stock in the short term. While the increase in price target is a positive signal, the 'Market Perform' rating suggests that the stock is expected to perform in line with the market, indicating no significant outperformance.